For research use only. Not for therapeutic Use.
Fimasartan（Cat No.:I002835）is an angiotensin II receptor blocker (ARB) primarily used for the treatment of hypertension and heart failure. By selectively blocking the angiotensin II type 1 (AT1) receptor, Fimasartan prevents the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to blood vessel relaxation and reduced blood pressure. It also helps protect the heart and kidneys by reducing the workload on these organs. Fimasartan is known for its fast onset and long-lasting effects, making it an effective option for managing hypertension with once-daily dosing.
| Catalog Number | I002835 |
| CAS Number | 247257-48-3 |
| Synonyms | 2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide |
| Molecular Formula | C27H31N7OS |
| Purity | ≥95% |
| Target | Angiotensin Receptor |
| Solubility | DMSO:49mg/mL |
| Storage | 2-8°C |
| IUPAC Name | 2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide |
| InChI | InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32) |
| InChIKey | AMEROGPZOLAFBN-UHFFFAOYSA-N |
| SMILES | CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C |
| Reference | </br>1:Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPAR<i>δ</i> Regulation in Hyperlipidemic and Hypertensive Conditions. Lee YJ, Jang YN, Han YM, Kim HM, Jeong JM, Seo HS.PPAR Res. 2017;2017:8048720. doi: 10.1155/2017/8048720. Epub 2017 Mar 13. PMID: 28386270 Free PMC Article</br>2:Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertension. Cardona-Muñoz EG, López-Alvarado A, Conde-Carmona I, Sánchez-Mejorada G, Pascoe-González S, Banda-Elizondo RG, García-Castillo A, González-Gálvez G, Velasco-Sánchez RG, Vidrio-Velázquez M, Leiva-Pons JL, Villeda-Espinosa E, Guerra-López A, Esturau-Santalo RM.Arch Cardiol Mex. 2017 Feb 10. pii: S1405-9940(17)30001-0. doi: 10.1016/j.acmx.2017.01.001. [Epub ahead of print] PMID: 28209359 </br>3:The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia. Rhee MY, Ahn T, Chang K, Chae SC, Yang TH, Shim WJ, Kang TS, Ryu JK, Nah DY, Park TH, Chae IH, Park SW, Lee HY, Tahk SJ, Yoon YW, Shim CY, Shin DG, Seo HS, Lee SY, Kim DI, Kwan J, Joo SJ, Jeong MH, Jeong JO, Sung KC, Kim SY, Kim SH, Chun KJ, Oh DJ.BMC Pharmacol Toxicol. 2017 Jan 5;18(1):2. doi: 10.1186/s40360-016-0112-7. PMID: 28057081 Free PMC Article</br>4:Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. Kang WY, Kim EH, Seong SJ, Gwon MR, Yang DH, Kim HJ, Lim MS, Lee HW, Yoon YR.Int J Clin Pharmacol Ther. 2016 Dec;54(12):992-1003. PMID: 27668695 </br>5:A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. Kim KI, Shin MS, Ihm SH, Youn HJ, Sung KC, Chae SC, Nam CW, Seo HS, Park SM, Rhee MY, Kim MH, Cha KS, Kim YJ, Kim JJ, Chun KJ, Yoo BS, Park S, Shin ES, Kim DS, Il Kim D, Kim KH, Joo SJ, Jeong JO, Shin J, Kim CH.Clin Ther. 2016 Oct;38(10):2159-2170. doi: 10.1016/j.clinthera.2016.07.008. Epub 2016 Aug 5. PMID: 27502326 </br>6:Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats. Kim TH, Kim MG, Shin S, Chi YH, Paik SH, Lee JH, Yoo SD, Youn YS, Bulitta JB, Joo SH, Jeong SW, Weon KY, Shin BS.BMC Pharmacol Toxicol. 2016 Jul 26;17(1):35. doi: 10.1186/s40360-016-0080-y. PMID: 27459959 Free PMC Article</br>7:Fimasartan: A New Angiotensin Receptor Blocker. Lee HY, Oh BH.Drugs. 2016 Jul;76(10):1015-22. doi: 10.1007/s40265-016-0592-1. Review. PMID: 27272555 </br>8:Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension. Kim SY, Joo SJ, Shin MS, Kim C, Cho EJ, Sung KC, Kang SM, Kim DS, Lee SH, Hwang KK, Park JB.Medicine (Baltimore). 2016 May;95(22):e3764. doi: 10.1097/MD.0000000000003764. PMID: 27258507 Free PMC Article</br>9:Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension. Shin MS, Kang DR, Kim C, Cho EJ, Sung KC, Kang SM, Kim DS, Joo SJ, Lee SH, Hwang KK, Park JB.Drug Des Devel Ther. 2016 May 5;10:1573-80. doi: 10.2147/DDDT.S107433. eCollection 2016. PMID: 27217724 Free PMC Article</br>10:A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. Lee JH, Yang DH, Hwang JY, Hur SH, Cha TJ, Kim KS, Kim MH, Chun KJ, Cha GS, Hong GR, Lee SG, Kim DS, Kim DI, Chae SC.Clin Ther. 2016 Jun;38(6):1485-97. doi: 10.1016/j.clinthera.2016.04.005. Epub 2016 May 6. PMID: 27161546 |
